Clear Filter

Aug 17, 2023

NORTH CHICAGO, Ill., Aug. 17, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission has approved AQUIPTA® (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes AQUIPTA the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) treatment in the European Union for the preventive treatment of both chronic and episodic migraine.

Aug 01, 2023

IRVINE, Calif., Aug. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the first ever JUVÉDERM® Day on Wednesday, August 16, 2023. The celebration recognizes the aesthetics providers and patients who have made the JUVÉDERM® Collection of Fillers the number one chosen* collection of dermal fillers in the U.S.1 JUVÉDERM® Day provides both new and loyal consumers savings and exclusive offers through Allē, the Allergan Aesthetics loyalty program.

Jul 27, 2023

NORTH CHICAGO, Ill., July 27, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2023.

Jul 26, 2023

NORTH CHICAGO, Ill. and LA JOLLA, Calif., July 26, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest. This partnership is an expansion of the collaboration AbbVie and Scripps Research formed in 2019 to develop a broad range of potential new and novel therapeutics.

Jul 26, 2023

NORTH CHICAGO, Ill., July 26, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of SKYRIZI® (risankizumab) compared to Otezla® (apremilast) among adult patients with moderate plaque psoriasis eligible for systemic therapy.1 This study achieved all primary and ranked secondary endpoints with no new safety signals identified.1

Jul 24, 2023

-  First registered, randomized Phase 3 trial in hidradenitis suppurativa (HS) evaluating the efficacy and safety of upadacitinib (RINVOQ®) in adults and adolescents with moderate to severe HS1

Jul 21, 2023

NORTH CHICAGO, Ill., July 21, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of conditional marketing authorization for epcoritamab (TEPKINLY®) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The final European Commission decision on this indication for epcoritamab is anticipated later this year.

Jul 06, 2023

NORTH CHICAGO, Ill., July 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2023 financial results on Thursday, July 27, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website An archived edition of the session will be available later that day.

Jun 27, 2023

Based on the topline results of epcoritamab from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities to discuss next steps

Jun 26, 2023

– AbbVie's 2023 Week of Possibilities brings more than 14,000 employees together to participate in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact
Week of Possibilities is AbbVie's annual, global volunteering program that unites employees around the world with a single purpose: to give back to local communities through volunteering